Thus, the ability to accurately measure regional increases in CU individuals using simplified MRI-free processing of tau PET data has important implications for clinical trial design and for the real world setting if disease modifying treatments become available for CU individuals (Updated Appropriate Use Criteria for Amyloid and Tau PET in Alzheimer’s Disease,Rabinovici, et al., 2023). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.